SCHEMBL7108360

SCHEMBL7108360

CN(C(=O)O)c1cc(Cl)nc(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
S1PR2 O95136 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPK1 P28482 1/20 0.37
RXRA P19793 9/20 0.35
RXRB P28702 8/20 0.35
RXRG P48443 6/20 0.35
ATF1 P18846 1/20 0.35
NFKB1 P19838 1/20 0.35
POLB P06746 1/20 0.34
GPBAR1 Q8TDU6 1/20 0.34
KDM4E B2RXH2 2/20 0.33
GPR35 Q9HC97 1/20 0.33
FFAR1 O14842 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
GRM5 P41594 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092292 0.78 TPMT (0.44) SMN1; SMN2ALDH1A1RXRARXRBRXRG
SCHEMBL1400929 0.77 ALDH1A1 (0.46) ALDH1A1POLBKDM4EFFAR1KMT2A
SCHEMBL21816685 0.77 MAPT (0.40) SMN1; SMN2ALDH1A1MAPK1POLBKDM4E
SCHEMBL2097580 0.77 POLB (0.39) SMN1; SMN2ALDH1A1POLB
SCHEMBL15595426 0.74 PAX8 (0.44) S1PR2RXRARXRBRXRGATF1
SCHEMBL8551879 0.72 APP (0.41) S1PR2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL23060418 0.72 ATF1 (0.37) S1PR2SMN1; SMN2RXRARXRBRXRG
SCHEMBL465570 0.71 TPMT (0.46) ALDH1A1RXRARXRBRXRGKDM4E
SCHEMBL26624101 0.71 ATF1 (0.36) S1PR2RXRARXRBRXRGATF1
SCHEMBL21551640 0.71 RAB9A (0.42) SMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3166945-B1 NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF ST PHARM CO LTD (KR) 2019-10-09 EP disclosed
US-9914737-B2 Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof ST PHARM CO., LTD. (KR) 2018-03-13 US disclosed
US-20170145016-A1 NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF ST PHARM CO., LTD. (KR) 2017-05-25 US disclosed
EP-3166945-A2 NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF ST Pharm Co. Ltd. (KR) 2017-05-17 EP disclosed
WO-2016006974-A2 NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF ST PHARM CO., LTD. (KR) 2016-01-14 WO disclosed
EP-1345494-A2 DICHLOROPYRIDYL METHYLAMIDES Bayer CropScience AG (DE) 2003-09-24 EP disclosed
WO-2002050035-A2 INSECTICIDAL AND FUNGICIDAL (2,6-DICHLORO-4-PYRIDYL) METHYLCARBAMATES USED AS PLANT PROTECTIVE AGENTS BAYER CROPSCIENCE AG (DE) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170145016-A1 NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF TNKS1BP1, TNKS, TPI1 S1PR2 3942/4885SMN1; SMN2 1022/4885ALDH1A1 2244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.